Literature DB >> 27766186

Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma.

Maria Danielsen1, Andreas Kjaer2, Max Wu3, Lea Martineau4, Mehdi Nosrati4, Stanley Pl Leong4, Richard W Sagebiel4, James R Miller4, Mohammed Kashani-Sabet4.   

Abstract

Positron emission tomography/computed tomography (PET/CT) is an important tool to identify occult melanoma metastasis. To date, it is controversial which patients with primary cutaneous melanoma should have staging PET/CT. In this retrospective analysis of more than 800 consecutive patients with cutaneous melanoma, we sought to identify factors predictive of PET/CT positivity in the setting of newly-diagnosed high-risk primary melanoma to determine those patients most appropriate to undergo a PET/CT scan as part of their diagnostic work up. 167 patients with newly-diagnosed high-risk primary cutaneous melanoma underwent a PET/CT scan performed as part of their initial staging. Clinical and histologic factors were evaluated as possible predictors of melanoma metastasis identified on PET/CT scanning using both univariate and multivariate logistic regression. In all, 32 patients (19.2%) had a positive PET/CT finding of metastatic melanoma. In more than half of these patients (56.3%), PET/CT scanning identified disease that was not detectable on clinical examination. Mitotic rate, tumor thickness, lymphadenopathy, and bleeding were significantly predictive of PET/CT positivity. A combinatorial index constructed from these factors revealed a significant association between number of high-risk factors observed and prevalence of PET/CT positivity, which increased from 5.8% (with the presence of 0-2 factors) to 100.0%, when all four factors were present. These results indicate that combining clinical and histologic prognostic factors enables the identification of patients with a higher likelihood of a positive PET/CT scan.

Entities:  

Keywords:  FDG; Melanoma; PET; PET/CT; molecular imaging; nuclear medicine; skin cancer; staging

Year:  2016        PMID: 27766186      PMCID: PMC5069280     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  30 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma.

Authors:  A Eigtved; A P Andersson; K Dahlstrøm; A Rabøl; M Jensen; S Holm; S S Sørensen; K T Drzewiecki; L Højgaard; L Friberg
Journal:  Eur J Nucl Med       Date:  2000-01

3.  Preoperative imaging for early-stage cutaneous melanoma: predictors, usage, and utility at a single institution.

Authors:  Dana Haddad; Erin M Garvey; Laurie Mihalik; Barbara A Pockaj; Richard J Gray; Nabil Wasif
Journal:  Am J Surg       Date:  2013-10-12       Impact factor: 2.565

4.  Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.

Authors:  E Gellén; O Sántha; E Janka; I Juhász; Z Péter; I Erdei; R Lukács; N Fedinecz; L Galuska; É Remenyik; G Emri
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-03-09       Impact factor: 6.166

5.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

6.  Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma.

Authors:  Thomas A Aloia; Jeffrey E Gershenwald; Robert H Andtbacka; Marcella M Johnson; Christopher W Schacherer; Chaan S Ng; Janice N Cormier; Jeffrey E Lee; Merrick I Ross; Paul F Mansfield
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

7.  Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases.

Authors:  Tjeerd S Aukema; Renato A Valdés Olmos; Michel W J M Wouters; W Martin C Klop; Bin B R Kroon; Wouter V Vogel; Omgo E Nieweg
Journal:  Ann Surg Oncol       Date:  2010-04-27       Impact factor: 5.344

8.  Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.

Authors:  Jeffrey D Wagner; Donald Schauwecker; Darrell Davidson; Theodore Logan; John J Coleman; Gary Hutchins; Charlene Love; Stacie Wenck; Joanne Daggy
Journal:  Cancer       Date:  2005-08-01       Impact factor: 6.860

9.  Sentinel-node biopsy or nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

10.  Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.

Authors:  Paige B Clark; Victoria Soo; Jonathan Kraas; Perry Shen; Edward A Levine
Journal:  Arch Surg       Date:  2006-03
View more
  2 in total

Review 1.  PET and SPECT imaging of melanoma: the state of the art.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quanyong Luo; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-30       Impact factor: 9.236

Review 2.  The challenge of primary gastric melanoma: a systematic review.

Authors:  Gregory S Mellotte; Diya Sabu; Mary O'Reilly; Ray McDermott; Anthony O'Connor; Barbara M Ryan
Journal:  Melanoma Manag       Date:  2020-11-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.